← Pharmacy curriculum
Module 16810 lessonsRxPrep 2023 Chapter 23, reconciled with the 2021 IDSA and SHEA focused update, 2024 AGA microbiota therapy guideline, 2026 CDC clinical guidance, and current FDA labeling

Clostridioides difficile Infection

Separate colonization from toxin-mediated disease, grade severity, choose recurrence-sparing therapy, recognize fulminant physiology, restore colonization resistance when indicated, and interrupt spore transmission.

01

Explain how antibiotic pressure, spores, toxins, and host response produce CDI.

02

Test only clinically compatible diarrhea and interpret multistep algorithms without treating colonization.

03

Grade nonsevere, severe, and fulminant disease while recognizing early surgical triggers.

04

Select current first-episode therapy according to efficacy, recurrence risk, access, and patient factors.

05

Stabilize fulminant CDI with enteral vancomycin, systemic adjunctive therapy, and urgent multidisciplinary care.

06

Treat first recurrence with a recurrence-sparing strategy and a clear risk assessment.

07

Use microbiota-based therapies and other recurrence strategies within current evidence and labeling.

08

Apply contact precautions, sporicidal cleaning, hand hygiene, and antimicrobial stewardship.

09

Adapt diagnosis and therapy for pregnancy, pediatrics, inflammatory bowel disease, and immune compromise.

10

Monitor response, toxicity, recurrence, transitions, and communication without ordering tests of cure.

168.01

Lesson

Understand the Ecologic Injury Before Choosing a Drug

CDI begins when antimicrobial pressure weakens colonization resistance and toxigenic organisms exploit the disrupted intestinal ecosystem.

What to learn
  • Spores
  • Colonization resistance
  • Toxin A
  • Toxin B
  • Inflammation
Clinical pathwayFrom exposure to disease
01SporesDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02DisruptionChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03ToxinsCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04ColitisOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Map the sequence

Ingested spores survive gastric transit, germinate in a permissive colon, expand after microbiome disruption, and produce toxins that injure epithelium and trigger inflammation.

Separate carriage from disease

A person can carry a toxigenic organism without toxin-mediated symptoms. Infection requires a compatible clinical syndrome plus supportive testing.

Name the strongest drivers

Recent antibiotics, prior CDI, age at least 65 years, recent healthcare exposure, serious illness, and immune compromise increase risk. Clindamycin, later-generation cephalosporins, fluoroquinolones, and carbapenems are prominent antibiotic risks.

Remove avoidable pressure

Stop unnecessary inciting antibiotics and reassess acid suppression, but continue a proton pump inhibitor when a valid indication outweighs theoretical CDI risk.

Quick check

0 of 1 answered
01What distinguishes CDI from asymptomatic colonization?
Answer every question to submit.
168.02

Lesson

Test Diarrhea, Not the Microbiome

Diagnostic accuracy begins before the sample reaches the laboratory. Pretest probability and specimen stewardship prevent false disease labels.

What to learn
  • Three stools
  • Unformed specimen
  • NAAT
  • GDH
  • Toxin assay
Clinical pathwayTest the right patient
01SymptomsDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02SpecimenChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03AlgorithmCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04InterpretOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Choose the patient

Test a patient with new unexplained clinically significant diarrhea, commonly at least three unformed stools in 24 hours, after considering laxatives, tube feeding, chemotherapy, inflammatory disease, and other causes.

Choose the specimen

Send fresh unformed stool. Do not test formed stool or screen asymptomatic patients as routine clinical practice.

Interpret the algorithm

NAAT is sensitive for toxigenic genes but can detect colonization. GDH is sensitive but nonspecific. A multistep strategy that combines a sensitive screen with a toxin assay improves interpretation when stool-submission criteria are inconsistent.

Do not test cure

Clinical recovery closes the episode. Tests can remain positive for six weeks or longer, so repeat testing after symptom resolution can create harmful retreatment.

Quick check

0 of 1 answered
01Which specimen is appropriate for routine CDI testing?
Answer every question to submit.
168.03

Lesson

Grade Severity Without Missing Fulminant Physiology

Laboratory thresholds help stage disease, but shock, ileus, megacolon, perforation, lactate, trajectory, and organ failure determine urgency.

What to learn
  • WBC
  • Creatinine
  • Shock
  • Ileus
  • Megacolon
Clinical pathwayGrade and escalate
01NonsevereDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02SevereChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03FulminantCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04SurgeryOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Classify nonfulminant disease

Traditional adult criteria describe nonsevere disease with leukocytosis no greater than 15,000 cells per cubic millimeter and serum creatinine below 1.5 mg/dL. Either value beyond that frame supports severe disease.

Recognize fulminant disease

Hypotension or shock, ileus, or toxic megacolon defines fulminant CDI. Rising lactate, peritonitis, organ failure, perforation, and rapid deterioration intensify the emergency.

Do not let diarrhea reassure

Ileus can reduce stool output despite worsening toxin-mediated colitis. Abdominal distention, systemic toxicity, and imaging may matter more than stool frequency.

Call early

Fulminant disease requires immediate infectious diseases, surgery, critical care, and gastroenterology coordination. Delay can remove the window for life-saving intervention.

Quick check

0 of 1 answered
01Which finding defines fulminant CDI?
Answer every question to submit.
168.04

Lesson

Use Recurrence-Sparing Therapy for the Initial Episode

For an initial nonfulminant episode, fidaxomicin is preferred when feasible because sustained response is better, while oral vancomycin remains an acceptable alternative.

What to learn
  • Fidaxomicin
  • Vancomycin
  • Metronidazole boundary
  • Access
  • Stop drivers
Clinical pathwayTreat the first episode
01Stop driversDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02FidaxomicinChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03VancomycinCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04FollowOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Prefer fidaxomicin when feasible

Use fidaxomicin 200 mg orally twice daily for 10 days for an eligible initial episode. Its narrow intestinal activity and lower recurrence risk drive preference.

Retain vancomycin as a valid option

Use vancomycin 125 mg orally four times daily for 10 days when fidaxomicin is unavailable, unaffordable, or otherwise unsuitable.

Narrow metronidazole use

Metronidazole is no longer preferred. It may be considered only for an initial nonsevere episode when fidaxomicin and oral vancomycin are unavailable, with close response monitoring.

Treat the ecosystem too

Stop unnecessary inciting antibiotics, avoid antimotility monotherapy in uncontrolled disease, maintain hydration and electrolytes, and document a recurrence plan.

Quick check

0 of 1 answered
01What is preferred for an eligible initial nonfulminant CDI episode when feasible?
Answer every question to submit.
168.05

Lesson

Deliver Drug to a Failing Gut While Preparing for Rescue

Fulminant CDI is a resuscitation and source-control emergency. The regimen must reach the bowel despite ileus and cannot substitute for surgical readiness.

What to learn
  • Vancomycin 500 mg
  • IV metronidazole
  • Rectal vancomycin
  • Resuscitation
  • Surgery
Clinical pathwayStabilize fulminant CDI
01ResuscitateDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02Enteral drugChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03IV supportCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04OperateOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Use high-dose enteral vancomycin

Give vancomycin 500 mg orally or through a nasogastric tube four times daily. IV vancomycin does not treat colonic CDI.

Add systemic adjunctive therapy

Add metronidazole 500 mg IV every 8 hours, especially when ileus can limit luminal delivery.

Bridge ileus deliberately

Consider rectal vancomycin when ileus is present, using an institutionally standardized preparation and administration process with specialist oversight.

Prepare definitive rescue

Resuscitate fluids and electrolytes, trend lactate and organs, stop avoidable drivers, and obtain urgent surgical consultation for worsening shock, megacolon, perforation, peritonitis, or failure.

Quick check

0 of 1 answered
01Which regimen matches fulminant CDI with ileus?
Answer every question to submit.
168.06

Lesson

Treat Recurrence as a New Decision, Not a Replay

Return of compatible symptoms after initial response requires renewed diagnostic discipline and a regimen chosen to reduce another recurrence.

What to learn
  • Confirm symptoms
  • Fidaxomicin
  • Extended pulse
  • Vancomycin taper
  • Risk factors
Clinical pathwayBreak the first recurrence
01ConfirmDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02FidaxomicinChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03Taper optionCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04Risk planOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Confirm the syndrome again

Do not treat a persistently positive assay without recurrent diarrhea. Reassess other causes, severity, prior response, and exposure.

Use fidaxomicin preferentially

A standard or extended-pulsed fidaxomicin regimen is suggested over a standard vancomycin course for recurrent disease when feasible.

Use vancomycin taper when appropriate

A tapered and pulsed oral vancomycin regimen is an acceptable first-recurrence alternative. A standard course can also be acceptable when the initial episode used metronidazole.

Name recurrence risk

Age at least 65 years, immune compromise, severe CDI, prior episodes, and continued antibiotic pressure raise recurrence risk and should shape follow-up and adjunct discussions.

Quick check

0 of 1 answered
01Which strategy is preferred for an eligible recurrent CDI episode when feasible?
Answer every question to submit.
168.07

Lesson

Restore Colonization Resistance After Repeated Disease

Repeated recurrence reflects ecosystem failure as well as residual susceptibility. After antibacterial treatment, selected patients can receive microbiota-based recurrence prevention.

What to learn
  • VOWST
  • REBYOTA
  • Conventional FMT
  • Eligibility
  • Safety
Clinical pathwayRestore colonization resistance
01AntibioticDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02MicrobiotaChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03EligibilityCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04PreventOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Know the product boundary

VOWST is oral and REBYOTA is rectal. Both are indicated in adults to prevent recurrence after antibacterial treatment for recurrent CDI, not to treat uncontrolled acute disease.

Use guideline-supported restoration

The 2024 AGA guideline suggests fecal microbiota-based therapy after standard antibiotics for recurrent CDI in immunocompetent adults and selected mildly or moderately immunocompromised adults.

Respect immune boundaries

AGA suggests against routine fecal microbiota-based therapy in severely immunocompromised adults because safety and benefit are uncertain.

Keep alternatives visible

Other multiple-recurrence options include fidaxomicin, tapered and pulsed vancomycin, or vancomycin followed by rifaximin. Product access, prior response, interactions, and preference determine fit.

Quick check

0 of 1 answered
01What is the FDA-labeled role of VOWST?
Answer every question to submit.
168.08

Lesson

Interrupt Spores at Every Transfer Point

Clinical treatment and transmission prevention are inseparable because spores persist on hands, equipment, rooms, and shared environments.

What to learn
  • Contact precautions
  • Soap and water
  • Dedicated equipment
  • List K sporicide
  • Antibiotic stewardship
Clinical pathwayInterrupt transmission
01IsolateDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02Gloves and gownChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03SporicideCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04StewardOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Isolate on suspicion

Place a symptomatic patient on contact precautions in a single room with a dedicated toilet while evaluation is underway.

Use barriers and hand hygiene

Wear gown and gloves. Follow facility hand-hygiene policy, and emphasize soap and water when spore removal is needed, especially during outbreaks or visible contamination.

Clean for spores

Use an EPA List K sporicidal agent for daily and terminal room cleaning and disinfect shared equipment before reuse.

Continue long enough

Maintain contact precautions for at least 48 hours after diarrhea resolves, with longer duration considered according to facility policy and ongoing transmission risk.

Quick check

0 of 1 answered
01Which environmental approach is recommended for a CDI room?
Answer every question to submit.
168.09

Lesson

Preserve the Syndrome While Adapting the Patient

Pregnancy, childhood, inflammatory bowel disease, immune compromise, and critical illness change risk, evidence, and monitoring without changing the need for a compatible syndrome.

What to learn
  • Pregnancy
  • Pediatrics
  • IBD
  • Immunocompromise
  • Renal function
Clinical pathwayIndividualize the risk
01PregnancyDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02ChildrenChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03IBDCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04ImmunityOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Use narrative pregnancy assessment

Do not use obsolete pregnancy letters. Document maternal disease risk, systemic absorption, available human data, lactation information, and specialist input for the selected regimen.

Use pediatric guidance

Children require age- and weight-specific diagnostic and treatment pathways. Avoid importing adult dose totals without pediatric verification.

Test IBD flares thoughtfully

A new or worsening inflammatory bowel disease flare can coexist with CDI. Test compatible diarrhea, treat infection, and coordinate immune therapy rather than assuming a single cause.

Screen microbiota candidates carefully

Severe immune compromise, transmissible-pathogen risk, product safety, and regulatory status materially change the microbiota restoration decision.

Quick check

0 of 1 answered
01How should pregnancy safety be presented for CDI treatment?
Answer every question to submit.
168.10

Lesson

Close the Episode Without Creating the Next One

Response monitoring, medication reconciliation, recurrence education, and handoff ownership prevent deterioration and unnecessary retreatment.

What to learn
  • Stool trend
  • Hydration
  • Laboratory trajectory
  • Recurrence
  • Handoff
Clinical pathwayOwn the full course
01ResponseDefine the state

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

02ToxicityChoose the intervention

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

03RecurrenceCheck the boundary

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

04HandoffOwn the next decision

Connect this step to symptoms, exposure, recurrence risk, organ function, and the next reassessment.

Measure clinical response

Follow stool frequency and character, abdominal pain and distention, oral intake, volume status, temperature, leukocytosis, creatinine, lactate when indicated, and organ function.

Audit treatment exposure

Verify oral delivery, dose, duration, access, adherence, interacting antibiotics, avoidable acid suppression, antimotility use, and adverse effects.

Teach recurrence

Explain that recurrent watery diarrhea after initial improvement requires prompt reassessment, while a positive test without symptoms does not justify treatment.

Write a complete handoff

Document episode number, severity, regimen and last dose, inciting antibiotics, isolation status, recurrence plan, microbiota therapy eligibility, warning signs, and follow-up owner.

Quick check

0 of 1 answered
01What is the best way to confirm CDI cure after symptoms resolve?
Answer every question to submit.

Module test

Check the connections.

Each attempt draws 10 questions from the complete 130 question bank.

130 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

References

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. IDSA and SHEA 2021 CDI Focused Update
  2. CDC 2026 CDI Clinical Guidance
  3. AGA 2024 Microbiota Therapy Guideline
  4. FDA VOWST
  5. FDA REBYOTA
PharmacyOpen tools